|
2023
|
Invention
|
Methods for the treatment of dyskinesia in cerebral palsy.
The disclosure is directed to methods... |
|
|
Invention
|
Osmotic dosage forms comprising deutetrabenazine and methods of use thereof. e.g.,e.g., hyperkine... |
|
|
Invention
|
Pharmaceutical formulations.
The present invention relates to new extended release pharmaceutica... |
|
2022
|
Invention
|
Multiparticulate dosage forms comprising deutetrabenazine.
Provided herein are modified release ... |
|
|
Invention
|
Multiparticulate dosage forms comprising deutetrabenazine. Provided herein are modified release m... |
|
|
Invention
|
Benzoquinoline inhibitors of vesicular monoamine transporter 2.
The present invention relates to... |
|
2021
|
Invention
|
Analogs of deutetrabenazine, their preparation and use.
The disclosure is directed to deutetrabe... |
|
|
Invention
|
Gastro retentive dosage forms comprising deutetrabenazine. e.g.,e.g., hyperkinetic movement disor... |
|
|
Invention
|
Multiparticulate dosage forms comprising deutetrabenazine. Provided herein are controlled release... |
|
|
Invention
|
Dihydroxyphenyl neurotransmitter compounds, compositions and methods.
The present invention rela... |
|
|
Invention
|
Osmotic dosage forms comprising deutetrabenazine and methods of use thereof. e.g.e.g., hyperkinet... |
|
|
Invention
|
Benzoquinolone inhibitors of vmat2.
The present invention relates to new benzoquinolone inhibito... |
|
|
Invention
|
Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine ... |
|
|
Invention
|
Novel pharmaceutical formulations.
The present invention relates to new extended release pharmac... |
|
2020
|
Invention
|
Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds.
Described are deuterium... |
|
|
Invention
|
Methods of manufacturing benzoquinoline compounds.
The present invention relates to new methods ... |
|
2019
|
Invention
|
Methods for the treatment of dyskinesia in cerebral palsy. The disclosure is directed to methods ... |
|
|
Invention
|
Deutetrabenazine for the treatment of dyskinesia in cerebral palsy. The disclosure is directed to... |
|
|
Invention
|
Pharmaceutical formulations. The present invention relates to new extended release pharmaceutical... |
|
2018
|
Invention
|
Cyclopropane carboxamide modulators of cystic fibrosis transmembrane conductance regulator. The p... |
|
|
Invention
|
Tetrahydrocarbazole inhibitors of sirt1 receptors.
Described are deuterium-substituted tetrahydr... |
|
2017
|
Invention
|
Deuterated aminopyridine compounds. The present disclosure is directed to Compound I and Compound... |
|
|
Invention
|
Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds. Described are deuterium-... |
|
|
Invention
|
Deuterium-substituted oxazepin compounds. Described are deuterium-substituted oxazepin compounds ... |
|
|
Invention
|
Deuterium-substituted oxazepin compounds.
Described are deuterium-substituted oxazepin compounds... |
|
|
Invention
|
Azetidine modulators of the sphingosine 1-phosphate receptor.
Described are deuterium-substitute... |
|
|
Invention
|
Azetidine modulators of the sphingosine 1-phosphate receptor. Described are deuterium-substituted... |
|
2016
|
Invention
|
Deuterated chlorokynurenines for the treatment of neuropsychiatric disorders.
Described are deut... |
|
|
Invention
|
Deuterium-substituted oxadiazoles.
Described are deuterated modulators of S1P1 receptors, pharma... |
|
|
Invention
|
Dimethoxyphenyl inhibitors of vesicular monoamine transporter 2. Described are dimethoxyphenyl in... |
|
2015
|
Invention
|
Cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator. The pr... |
